Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-?B, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.

ABSTRACT: Escape from immune control must be important in the natural course of B-cell lymphomas, especially for those with activation of NF-?B. The pre-clinical LMP1/CD40-expressing transgenic mouse model is characterized by B-cell specific CD40 signaling responsible for NF-?B continuous activation with a spleen monoclonal B-cell tumor after 1 year in 60% of cases. LMP1/CD40 tumors B-cells expressed high levels of PD-L1. This expression was dependent on activation of either NF-?B, JAK1/JAK2 or BTK pathways since these pathways were activated in tumor B-cells and ex vivo treatment with the inhibitory molecules PHA-408, ruxolitinib and ibrutinib led to decrease of its expression. Treatment of LMP1/CD40-expressing lymphomatous mice with an anti-PD-L1 monoclonal antibody induced tumor regression with decreased spleen content, activation and proliferation rate of B-cells as well as a marked increase in T-cell activation, as assessed by CD62L and CD44 expression. These results highlight the interest of therapies targeting the PD-1/PD-L1 axis in activated lymphomas with PD-L1 expression, with possible synergies with tyrosine kinase inhibitors.

SUBMITTER: Vincent-Fabert C 

PROVIDER: S-EPMC6683395 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature